Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials

Dow Jones

2025/07/07

By Adriano Marchese

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment.

Shares traded 36% higher ahead of the morning bell at $64.45.

The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives.

The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life.

Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

Apogee Therapeutics announced results from the phase 2 APEX Part A clinical trial for APG777. "Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials," at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial.

(END) Dow Jones Newswires

July 07, 2025 09:44 ET (13:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549416535"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549416535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549416535?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-07 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549416535","market":"sh","top_or_hot":-1,"title":"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n</p>\n<p>\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n</p>\n<p>\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n</p>\n<p>\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n</p>\n<p>\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2025 09:44 ET (13:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-07 18:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n</p>\n<p>\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n</p>\n<p>\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n</p>\n<p>\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n</p>\n<p>\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2025 09:44 ET (13:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2549416535","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549416535","pubTimestamp":1751884320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment.Shares traded 36% higher ahead of the morning bell at $64.45.The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives.The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life.Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APGE":"Apogee Therapeutics"},"translate_title":"Apogee Therapeutics因皮炎治疗试验的积极数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APGE":1},"content_text":"By Adriano Marchese \n\n\n \n\n\nApogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n\n\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n\n\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n\n\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n\n\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n \n\n\n  Apogee Therapeutics announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 07, 2025 09:44 ET (13:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}